ARTICLE | Clinical News
Botox onabotulinumtoxinA regulatory update
February 20, 2012 8:00 AM UTC
Allergan disclosed in its 4Q11 earnings that Health Canada approved Botox onabotulinumtoxinA as a prophylactic to treat chronic migraine in adults. GlaxoSmithKline has rights from Allergan to develop ...